FY2026 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Immunic in a research note issued on Monday, March 24th. William Blair analyst M. Minter forecasts that the company will earn ($0.98) per share for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

Other analysts have also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Immunic in a report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. Finally, StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.67.

Immunic Stock Down 3.2 %

Shares of NASDAQ:IMUX opened at $1.20 on Thursday. The company has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $1.21. The firm has a market capitalization of $108.09 million, a PE ratio of -0.98 and a beta of 1.89. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11.

Institutional Trading of Immunic

A number of hedge funds have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. State Street Corp grew its stake in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Jane Street Group LLC increased its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Virtu Financial LLC purchased a new position in Immunic during the third quarter valued at $50,000. Finally, HB Wealth Management LLC bought a new stake in Immunic in the fourth quarter worth $81,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.